酒精性肝病诊断现状

doi:10.3969/j.issn.1672-5069.2014.01.003

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (1): 9-11.doi: 10.3969/j.issn.1672-5069.2014.01.003

酒精性肝病诊断现状

李良平

610072 成都市四川省人民医院消化内科

收稿日期:2013-10-17 出版日期:2014-02-28 发布日期:2016-04-11
作者简介:李良平,教授,主要从事慢性肝病的诊治研究。E-mail： llp0131@medmail.com.cn

Diagnosis of alcoholic liver disease

Li Liangping

Department of Gastroenterology,Provincial Hospital,Chengdu 610072

Received:2013-10-17 Online:2014-02-28 Published:2016-04-11

摘要/Abstract

摘要： 酒精性肝病（Alcoholic liver disease,ALD）是西方国家最常见的肝病。在法国,l/3以上肝硬化病因是过量饮酒。在美国,酒精性肝硬化是最常见死亡原因的第8位,在胃肠道疾病中,其死亡率位列第二^[1]。我国酒精的消耗量也在不断增加。尽管中国缺乏大规模ALD的流行病学调查资料,但几个局部地区的报道发现ALD的发病比例在不断上升^[2,3]。同时,我国还面临较多的酒精性肝病和/或非酒精性脂肪性肝病（non-alcoholic fatty liver disease,NAFLD）合并病毒性肝病的现实问题。

关键词: 酒精性肝病, 酒精性肝炎, 诊断

Key words: Alcoholic liver disease, Alcoholic hepatitis, Diagnosis

李良平. 酒精性肝病诊断现状[J]. 实用肝脏病杂志, 2014, 17(1): 9-11.

Li Liangping. Diagnosis of alcoholic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 9-11.

参考文献

[1] Asrani SK,Kamath PS,Pedersen R,et al. Liver related mortality in the US is underestimated. Hepatology,2010,52：408A.
[2] 历有名,陈卫星,虞朝辉,等. 浙江省酒精性肝病流行病学调查慨况. 中华肝脏病杂志,2003,1：647-649.
[3] 黄顺玲,戴水奇,张雪红,等. 湖南省酒精性肝病流行病学调查慨况. 中国医师杂志,2005,7：426-427.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志,2010,18（3）：163-166.
[5] European Association for the Study of Liver.EASL clinical practical guidelines：management of alcoholic liver disease.J Hepatol,2012,57（2）：399-420.
[6] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease：practice guideline by the American Association for the Study of Liver Diseases,American College of Gastroenterology,and the American Gastroenterological Association. Hepatology,2012,55（6）：2005-2023.
[7] Dunn W,Sanyal AJ,Brunt EM,et a1.Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease. J Hepatol,2012,57（2）：387-391.
[8] Rehm J,Taylor B,Mohapatra S,et al.Alcohol as a risk factor for liver cirrhosis：a systematic review and meta-analysis. Drug Alcohol Rev,2010,29（4）：437-445.
[9] O’Shea RS,Dasarathy S,McCullough AJ. Alcoholic liver disease. Practice Guideline Committee of the American Association for the Study of Liver Diseases;Practice Parameters Committee of the American College of Gastroenterology. Hepatology,2010,51（1）：307-328.
[10] Piano SM,Rosi S,Cavallin M,et al. Urinary ethyl glucuronide improves the detection of alcohol consumption in liver transplant candidates and recipients. Hepatology,2012,56：977A.
[11] Stewart SH,Koch DG,Burgess DM,et al. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients.Alcohol Clin Exp Res,2013,37（1）：150-155.
[12] Staufer K,Andresen H,Vettorazzi E,et al. Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology,2011,54（5）：1640-1649.
[13] Lucey MR,Mathurin P,Morgan TR. Alcoholic hepatitis. N Engl J Med,2009,360：2758-2769.
[14] Singal AK,Shah VH. Alcoholic hepatitis：prognostic models and treatment. Gastroenterol Clin N Am,2011,40：611-639.
[15] Dunn W,Angulo P,Sanderson S,et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology,2006,131（4）：1057-1063.
[16] Singal1 A,Kamath1 PS,Gores GJ,et al. Alcoholic hepatitis： Current challenges and future directions. Clin Gastroenterol Hepatol,2013,doi:10.1016/j.cgh.2013.06.013. [Epub ahead of print]
[17] Dunn W,Jamil LH,Brown LS,et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology,2005,41（2）：353-358.
[18] Louvet A,Naveau S,Abdelnour M,et al. The Lille model：a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology,2007,45（6）：1348-1354.
[19] Singal AK,Kuo YF,Anand BS. Hepatitis C virus infection in alcoholic hepatitis：prevalence patterns and impact on in-hospital mortality. Eur J Gastroenterol Hepatol,2012,24（10）：1178-1184.

酒精性肝病诊断现状

Diagnosis of alcoholic liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[5]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[6]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[7]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[10]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[14]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[15]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.